Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma
Yung Lyou, Petros Grivas, Jonathan E. Rosenberg, Jean Hoffman‐Censits, David I. Quinn, Daniel P. Petrylak, Matthew D. Galsky, Ulka N. Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A. Burris, Jessica Rearden, Ai Li, Hao Wang, Maribel Reyes, Susan Moran, Siamak Daneshmand, Dean F. Bajorin, Sumanta K. Pal
Topics & Concepts
MedicineHyperphosphatemiaFibroblast growth factor 23Fibroblast growth factor receptorUrothelial carcinomaFibroblast growth factorCancer researchFibroblast growth factor receptor 1Fibroblast growth factor receptor 2Fibroblast growth factor receptor 3FibroblastMetastatic Urothelial CarcinomaOncologyReceptorInternal medicineCancerBladder cancerKidney diseaseIn vitroCalciumBiochemistryBiologyParathyroid hormoneFibroblast Growth Factor ResearchParathyroid Disorders and TreatmentsBladder and Urothelial Cancer Treatments